Mont-Saint-Guibert, Belgium (March 10, 2025) –

Cellistic is pleased to announce the appointment of Tarran Pierfelice, PhD, MBA as its new Chief Commercial Officer, effective March 10, 2025.

With over a decade of experience in biopharma and contract services business development, Tarran joins Cellistic to lead its commercial initiatives. 

Previously to joining Cellistic, Tarran led the Gene Therapy Franchise at Resilience, managing a multi-million-dollar sales funnel that resulted in significant revenue growth and successful technology licensing and supply agreements. At Editas Medicine, Tarran played a crucial role in closing high-profile agreements related to CRISPR-based cell therapies. Her deep understanding of the needs of developers and her expertise in partnership development and strategic analysis have defined her career in advancing therapeutic innovations.

Tarran holds an MBA from Harvard Business School, a PhD in Cellular & Molecular Medicine from Johns Hopkins University School of Medicine, and a Bachelor of Science in Molecular Biology from the Florida Institute of Technology.

Tarran will report to Gustavo Mahler, Chief Executive Officer, and will be a member of the Cellistic Leadership Team.

 

“I am excited to join Cellistic to lead its commercial growth,” says Tarran. “As the field of cell therapies evolves, there is a critical need to shift towards scalable, cost-effective allogeneic approaches to improve patient accessibility. With its world-class talent and cutting-edge technologies, Cellistic is uniquely positioned to drive innovation and advance iPSC-based therapies for the future.”

 

About Cellistic®

Cellistic specializes in the process development and manufacturing of immune cell therapies based on human induced pluripotent stem cell (iPSC) technology, using their Pulse™ and Echo™ Platform. Its focus and expertise in iPSC reprogramming, gene editing using its proprietary STAR-CRISPR™ technology ,and differentiation development, positions the company to be the partner of choice for innovative cell therapy developers to advance into clinic. Leveraging more than a decade of scientific and technical knowledge and experience, Cellistic possesses unique capabilities for the design and optimization of proprietary manufacturing platforms for iPSC- based cell therapies.